Cobicistat
Tablet · trading as Tybost
To Be Discontinued
FDA shortage record
- Substance
- Cobicistat
- Brand name
- Tybost
- Manufacturer
- Gilead Sciences, Inc.
- Dosage form
- Tablet
- Presentation
- Tybost, Tablet, 150 mg (NDC 61958-1401-1)
- Route(s)
- ORAL
- Therapeutic category
- Antiviral
- Package NDC
61958-1401-1- Initially posted
- 10/07/2025
- Discontinued
- 10/07/2025
- Current FDA status
- To Be Discontinued
Reason and context
Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-445-3235.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
3784c35c-e87f-410c-900b-8fd6313c6010). - FDA UNII identifier:
LW2E03M5PG. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.